CYTEK BIOSCIENCES INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect each of our two Class III director nominees to our Board of Directors for a three-year term, to hold office until our 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Michael Holder

CYTEK BIOSCIENCES INC.’s own tally for this item (“Elect Director: Michael Holder”): 70,298,785 for, 3,793,589 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2027 annual meeting of stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal:”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 33,376,751 for.

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Description as filed by funds: To elect each of our two Class III director nominees to our Board of Directors for a three-year term, to hold office until our 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Wenbin Jiang, Ph.D.

CYTEK BIOSCIENCES INC.’s own tally for this item (“Elect Director: Wenbin Jiang, Ph.D.”): 64,177,338 for, 9,915,036 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2027 annual meeting of stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal:”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 31,520,972 for, 1,773,549 withheld, 82,230 abstained.

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Description as filed by funds: To vote, on an advisory basis, regarding the compensation of our named executive officers for the year ended December 31, 2023.

CYTEK BIOSCIENCES INC.’s own tally for this item (“2. Executive Compensation. On an advisory basis, compensation paid to the Company's named executive officers for the year ended December 31, 2023”): 63,537,386 for, 10,476,039 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “On an advisory basis, compensation paid to the Company's named executive officers for the year ended December 31, 2023 was approved based on the following results of voting:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 56 managers: 28,046,073 for, 5,334,909 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 127 managers: 28,493,948 for, 7,614,117 against, 184 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

CYTEK BIOSCIENCES INC.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December”): 94,116,564 for, 2,329,549 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 33,321,640 for, 59,542 against.

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.